S4-24 – Reviewing the 2023 Innovations in NAFLD Care Workshop
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg.
June 1, 2023
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. This final conversation explores hepatocellular ballooning and the power of AI-assisted pathological assessment.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. This conversation considers how to lower screen fail rates and the prospect of establishing guidelines for the biopsy reading process.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. The group considers what exactly is moving the field rapidly forward. The focus of this conversation considers the future of AI-assisted digital pathology, NITs and screen fail rates.
Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. This conversation features Stephen’s take on the recent outcome of the FDA ADCOM meeting for obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH.
Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. The group dives deep into a range of topics including drugs with strong metabolic foundations, the state of histopathology, clinical trial design and screen fail rates, FDA ADCOM on obeticholic acid and much more.
Donna Cryer joins Jörn Schattenberg and Roger Green for a session which draws from raw reflections on the recent FDA Advisory Committee meeting and its outcome for obeticholic acid. The group remains focused on a critical message that looks down the path forward for the liver community and meeting patient needs. Stay tuned for more coverage as SurfingNASH continues to meet with other KOLs and stakeholders to discuss the event and its implications.
Roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not).
Aleksander Krag and Sven Francque join the Surfers to discuss the upcoming EASL Congress taking place from June 21-24 in Vienna. The group explores the power of poster presentations and why someone should attend the virtual program if they can’t make it in person.
Aleksander Krag and Sven Francque join the Surfers to discuss the upcoming EASL Congress taking place from June 21-24 in Vienna. The group explores 3 “can’t miss” features for different participating parties and how the program was put together.